CHIPS-Child is a follow up study to the CHIPS (Control of Hypertension In Pregnancy Study) randomised controlled trial
There is now solid evidence that a reduced rate of growth before birth is associated with adult cardiovascular disease (like heart attack or stroke). The information comes from different populations around the world, and is true even when babies are born with normal birth weights. At present, the ‘Developmental Origins Hypothesis’ provides the best explanation. In response to decreased nutrition in the uterus, changes are made to the activity of fetal genes (the ‘code’ that determines our health and traits like height). These changes to gene activity are permanent, and after birth, set up the child’s metabolism in a way that may be harmful in the long-term (e.g., predispose to diabetes or high blood pressure).
The CHIPS-Child sub-study is designed to find out whether the way a mother’s blood pressure is managed during pregnancy may affect her baby’s(ies’) potential for growth before birth, and as a result, have long-lasting effects on the child such as diabetes or cardiovascular disease (such as high blood pressure or heart attack and stroke in adulthood).